

Mary E Rinella

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7478145/mary-e-rinella-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93
papers

11,680
citations

41
h-index

108
g-index

118
ext. papers

16,923
ext. citations

7.9
avg, IF

7.35
L-index

#	Paper	IF	Citations
93	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018 , 67, 328-357	11.2	2641
92	Nonalcoholic fatty liver disease: a systematic review. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 2263-73	27.4	1331
91	Mechanisms of NAFLD development and therapeutic strategies. <i>Nature Medicine</i> , 2018 , 24, 908-922	50.5	1110
90	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020 , 158, 1999-2014.e1	13.3	748
89	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	40	425
88	Nonalcoholic fatty liver disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15080	51.1	366
87	The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. <i>Journal of Hepatology</i> , 2004 , 40, 47-51	13.4	304
86	Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. <i>Journal of Lipid Research</i> , 2008 , 49, 1068-76	6.3	303
85	NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018 , 391, 1174-1185	40	256
84	Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. <i>Gastroenterology</i> , 2020 , 158, 1851-1864	13.3	238
83	Management of NAFLD: a stage-based approach. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 196-205	24.2	195
82	Body mass index as a predictor of hepatic steatosis in living liver donors. <i>Liver Transplantation</i> , 2001 , 7, 409-14	4.5	184
81	Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. <i>Hepatology</i> , 2015 , 62, 773-83	11.2	157
80	Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. <i>Gastroenterology</i> , 2018 , 155, 422-430.e1	13.3	155
79	Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. <i>Hepatology</i> , 2012 , 56, 1741-50	11.2	154
78	Non-alcoholic fatty liver disease. <i>Lancet, The</i> , 2021 , 397, 2212-2224	40	145
77	Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. <i>Annals of Hepatology</i> , 2011 , 10, 277-286	3.1	123

76	Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. <i>Clinics in Liver Disease</i> , 2015 , 19, 361-79	4.6	117
75	The role of diet and nutrient composition in nonalcoholic Fatty liver disease. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2012 , 112, 401-9	3.9	114
74	From NAFLD to MAFLD: Implications of a Premature Change in Terminology. <i>Hepatology</i> , 2021 , 73, 1194-1198	11.2	111
73	Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. <i>Hepatology</i> , 2020 , 72, 58-71	11.2	107
72	Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 696-703	6.1	106
71	Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. <i>Gastroenterology</i> , 2020 , 158, 1334-1345.e5	13.3	105
70	International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. <i>Transplantation</i> , 2018 , 102, 727-743	1.8	84
69	Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation. <i>Liver Transplantation</i> , 2003 , 9, 851-6	4.5	83
68	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019 , 84, 105803	2.3	72
67	Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2016 , 15, 75-85	1	71
66	Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. <i>Journal of Hepatology</i> , 2019 , 71, 823-833	13.4	64
65	Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. <i>Annals of Hepatology</i> , 2011 , 10, 277-86	3.1	59
64	The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. <i>Therapeutic Advances in Gastroenterology</i> , 2011 , 4, 249-63	4.7	56
63	Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis. <i>Hepatology</i> , 2011 , 54, 1600-9	11.2	51
62	NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015 , 12, 65-6	24.2	49
61	Practice patterns in NAFLD and NASH: real life differs from published guidelines. <i>Therapeutic Advances in Gastroenterology</i> , 2016 , 9, 4-12	4.7	48
60	Non-alcoholic fatty liver disease: is bariatric surgery the answer?. <i>Clinics in Liver Disease</i> , 2009 , 13, 689-710	10.6	45
59	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. <i>Contemporary Clinical Trials</i> , 2020 , 88, 105889	2.3	45

58	Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. <i>Hepatology</i> , 2019 , 70, 1424-1436	11.2	44
57	Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. <i>Liver International</i> , 2015 , 35, 2575-83	7.9	44
56	Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2019 , 70, 735-744	13.4	42
55	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. <i>Hepatology</i> , 2019 , 70, 1841-1855	11.2	41
54	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
53	Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. <i>Journal of the American Heart Association</i> , 2020 , 9, e014279	6	35
52	Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. <i>Gastroenterology</i> , 2020 , 159, 1985-1987.e4	13.3	34
51	Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. <i>American Journal of Gastroenterology</i> , 2017 , 112, 755-762	0.7	33
50	GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. <i>Journal of Hepatology</i> , 2019 , 70, e5	13.4	33
49	A myriad of pathways to NASH. <i>Clinics in Liver Disease</i> , 2012 , 16, 525-48	4.6	33
48	Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study. <i>Transplantation</i> , 2017 , 101, 2873-2882	1.8	32
47	NAFLD: Reporting Histologic Findings in Clinical Practice. <i>Hepatology</i> , 2021 , 73, 2028-2038	11.2	31
46	Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1387-97	4	25
45	Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis. <i>Gastroenterology</i> , 2019 , 157, 472-480.e5	13.3	25
44	Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study. <i>Journal of General Internal Medicine</i> , 2019 , 34, 2772-2778	4	25
43	Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. <i>Liver International</i> , 2018 , 38, 706-714	7.9	24
42	Controversies in the Diagnosis and Management of NAFLD and NASH. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 219-27	0.7	24
41	Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 513-526	6.1	23

40	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).. <i>Endocrine Practice</i> , 2022 , 28, 528-562	3.2	16
39	Liraglutide-induced autoimmune hepatitis. <i>JAMA Internal Medicine</i> , 2014 , 174, 984-7	11.5	15
38	Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. <i>American Journal of Gastroenterology</i> , 2019 , 114, 579-590	0.7	14
37	Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife. <i>American Journal of Gastroenterology</i> , 2019 , 114, 758-763	0.7	13
36	Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters. <i>Obesity</i> , 2019 , 27, 59-67	8	13
35	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021 , 161, 1475-1486	13.3	13
34	Intensive management of hepatic failure. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2006 , 27, 241-61	3.9	12
33	Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021 , 74, 274-282	13.4	12
32	Non-alcoholic fatty liver disease: Not time for an obituary just yet!. <i>Journal of Hepatology</i> , 2021 , 74, 972-974	3.4	12
31	Interpretation and management of hepatic abnormalities in pregnancy. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 1392-8	6.9	11
30	Medical and Obstetric Complications Among Pregnant Women With Liver Cirrhosis. <i>Obstetrics and Gynecology</i> , 2017 , 129, 1118-1123	4.9	10
29	Twenty-five-year trajectories of insulin resistance and pancreatic β cell response and diabetes risk in nonalcoholic fatty liver disease. <i>Liver International</i> , 2018 , 38, 2069-2081	7.9	10
28	Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis. <i>Liver International</i> , 2019 , 39, 933-940	7.9	10
27	Resting and Exercise Energy Metabolism After Liver Transplantation for Nonalcoholic Steatohepatitis. <i>Transplantation Direct</i> , 2017 , 3, e188	2.3	9
26	Hepatic overexpression of abcb11 promotes hypercholesterolemia and obesity in mice. <i>Gastroenterology</i> , 2011 , 141, 1404-11, 1411.e1-2	13.3	9
25	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	8
24	Preparing for the NASH Epidemic: A Call to Action. <i>Gastroenterology</i> , 2021 , 161, 1030-1042.e8	13.3	7
23	EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. <i>Journal of Hepatology</i> , 2021 ,	13.4	6

22	Moderate Exercise for Nonalcoholic Fatty Liver Disease. <i>JAMA Internal Medicine</i> , 2016 , 176, 1083-4	11.5	6
21	Fundal variceal bleeding after correction of portal hypertension in patients with cirrhosis. <i>Gastrointestinal Endoscopy</i> , 2003 , 58, 122-7	5.2	6
20	Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 3413-3430	4	5
19	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.. <i>Journal of Hepatology</i> , 2022 ,	13.4	5
18	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2021 ,	13.4	5
17	Preparing for the NASH Epidemic: A Call to Action. <i>Diabetes Care</i> , 2021 , 44, 2162-2172	14.6	5
16	OTU-14 Positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH 2019 ,		5
15	Real-World Burden of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1020-1029.e7	6.9	5
14	Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2019 , 51, 1895-1901	1.1	4
13	NAFLD and Cardiovascular Disease: Can the Real Association Be Determined?. <i>Current Hepatology Reports</i> , 2014 , 13, 130-141	1	4
12	Amelioration of hepatic inflammation in a mouse model of NASH using a dithiocarbamate derivative. <i>Hepatology International</i> , 2013 , 7, 600-9	8.8	4
11	Preparing for the NASH epidemic: A call to action. <i>Metabolism: Clinical and Experimental</i> , 2021 , 122, 1548-1557	12.7	4
10	Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	3
9	Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	3
8	Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 1472-1480	6.1	2
7	AuthorsResponse. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2013 , 113, 211-2	3.9	1
6	Preparing for the NASH epidemic: A call to action. <i>Obesity</i> , 2021 , 29, 1401-1412	8	1
5	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis 2018 , 68, 349		1

4	Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients. <i>Transplantation Direct</i> , 2021 , 7, e784	2.3	0
3	The Management of Pregnancy in Patients with Advanced Liver Disease Before and After Liver Transplantation. <i>Current Hepatology Reports</i> , 2016 , 15, 36-43	1	
2	An algorithm for the management of non-alcoholic fatty liver disease in primary care. <i>Gastroenterology & Hepatology (Bartlesville, Okla)</i> , 2021 , 12, 114-122	0.2	
1	938 Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. <i>American Journal of Gastroenterology</i> , 2019 , 114, S546-S546	0.7	